Novo Nordisk reports Phase III FRONTIER4 study results for denecimig

​

Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy of investigational Mim8 in patients with haemophilia A.

The post Novo Nordisk reports Phase III FRONTIER4 study results for denecimig appeared first on Hospital Management.

 

Back to the Featured Stories
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig

Featured Stories

Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Smith+Nephew unveils Lynx Coblation Laryngeal Wand for laryngology
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
Neuraptive secures exclusive licence from Washington University for nerve device

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us